Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Psoriatic arthritis PsA is a chronic inflammatory condition affecting the joints and skin of people with psoriasis PsO. This research aims to evaluate how well the drug zasocitinib works in adults with active PsA who have not previously been treated with biologic disease-modifying antirheumatic drugs. The study is a phase 3 trial comparing zasocitinib to an active comparator and placebo to assess treatment effects and safety. Participants are randomly assigned to one of four groups. One group receives zasocitinib Dose A orally once daily for up to 52 weeks, another group receives zasocitinib Dose B once daily for the same period, a third group receives the active comparator capsules twice daily for up to 52 weeks, and the fourth group receives placebo once daily for 16 weeks followed by zasocitinib Dose A or B from Week 16 to Week 52. This design allows comparison between different doses, placebo, and active treatments. During the study, participants will be monitored regularly with evaluations including joint assessments and skin lesion checks. Researchers will measure responses such as improvement in arthritis symptoms using the American College of Rheumatology 20 ACR20 response at Week 16 as the primary outcome. Secondary measures include skin improvement and various quality of life and disease activity scores. The study duration for participants is up to 60 weeks, including treatment and follow-up, to assess both efficacy and safety of the treatments.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Cordella Pulmonary Artery Sensor System in adults with New York Heart Association NYHA Class II and III heart failure. This multi-center, open-label, randomized controlled trial aims to assess how well this device helps manage heart failure by providing daily pulmonary artery pressure PAP measurements to clinicians and patients. The study includes multiple groups to compare different management strategies and patient self-management approaches. Participants will receive the Cordella Sensor device, which measures and transmits daily PAP data along with other vital signs such as blood pressure, weight, heart rate, and oxygen saturation. Clinicians will manage patients heart failure therapy based on these data using guideline-directed medical therapy. Some participants will follow a clinician-directed patient self-management plan involving daily PAP measurement and medication adjustments. The trial includes several study arms for both NYHA Class II and III cohorts, with some participants potentially crossing over between groups after a period. During the study, participants will take daily measurements using the Cordella system and attend scheduled follow-up visits. Researchers will monitor heart failure events, hospitalizations, mortality, device safety, and pressure sensor performance over months to years. The primary outcomes include heart failure events or cardiovascular death at 6 to 24 months, and safety outcomes related to device complications and sensor failure. Secondary outcomes cover hospitalization rates, medication changes, quality of life, functional status, and economic analyses. Participants are expected to comply with device use and follow-up visits throughout the trial duration, which may extend up to five years.